First Tracks Biotherapeutics, Inc. TRAX
First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) is a GI/hepatology drug developer. Its lead program, ANB033, is in Phase 2 for Celiac disease / Eosinophilic esophagitis.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ANB033 | Celiac disease | antibody | Phase 2 |
| ANB033 | Vitiligo and one additional indication | antibody | Phase 2 |
| Rosnilimab | Rheumatoid arthritis | antibody | Phase 2 |
| ANB033 | Eosinophilic esophagitis | antibody | Phase 1 |
| ANB101 | Autoimmune/inflammatory (BDCA2 modulator) | antibody | Phase 1 |
Recent results and decisions
- Nov 3, 2026completed enrollment Completed enrollment for Cohort 2 (mucosal healing) of Phase 1b ANB033 trial in celiac disease.
Enrollment complete with top-line data anticipated in Q1 2027
Filing - Oct 31, 2026met ANB033 achieved statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease.
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms
Filing - Oct 12, 2026met Cohort 1 met key endpoints: Vh:Cd change -0.17 vs -0.66 placebo (+0.49, p=0.009); IEL density -20.03 vs placebo (p<0.001); symptoms prevented; no SAEs.
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.